• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

中性粒细胞与淋巴细胞比值在肾脏肿瘤学中的预后价值:综述

The prognostic value of the neutrophil-lymphocyte ratio in renal oncology: A review.

作者信息

Boissier Romain, Campagna Jennifer, Branger Nicolas, Karsenty Gilles, Lechevallier Eric

机构信息

Aix-Marseille University, Marseille, France; Department of Urology and Renal Transplantation, APHM, Conception University Hospital, Marseille, France.

Aix-Marseille University, Marseille, France; Department of Urology and Renal Transplantation, APHM, Conception University Hospital, Marseille, France.

出版信息

Urol Oncol. 2017 Apr;35(4):135-141. doi: 10.1016/j.urolonc.2017.01.016. Epub 2017 Feb 21.

DOI:10.1016/j.urolonc.2017.01.016
PMID:28233671
Abstract

BACKGROUND

The neutrophil-lymphocyte ratio (NLR) is a biological marker of inflammation with a significant prognostic value in the field of oncology.

AIM

In this review, we discuss the prognostic value of the NLR in renal cell carcinoma (RCC).

MATERIAL AND METHOD

We conducted a literature review of the PubMed database in August 2016. Initial research identified 31 publications. Following full-text screening, 15 studies were finally included: 7 studies concerning metastatic or locally advanced renal cancer, 6 studies dealing with localized renal cancer, 2 articles evaluating the NLR in renal cancer whatever the status of the disease (metastatic or localized).

RESULTS

For localized RCC, an NLR o 3 was predictive of a reduced risk of recurrence (hazard ratio ¼ 1.63 [1.15, 2.29]). The prognostic value of the NLR was stronger for metastatic or locally advanced RCC. An NLR o 3 predicted increased overall survival (hazard ratio ¼ 1.55 [1.36, 1.76]), progression-free survivals (hazard ratio ¼ 3.19 [2.23, 4.57]), and a response to systemic treatment.

CONCLUSION

In current practice, the NLR is a simple and inexpensive prognostic factor with potential improvement in the prognostic performance of nomograms used in renal oncology.

摘要

背景

中性粒细胞与淋巴细胞比值(NLR)是一种炎症生物标志物,在肿瘤学领域具有重要的预后价值。

目的

在本综述中,我们讨论NLR在肾细胞癌(RCC)中的预后价值。

材料与方法

我们于2016年8月对PubMed数据库进行了文献综述。初步检索确定了31篇出版物。经过全文筛选,最终纳入15项研究:7项关于转移性或局部晚期肾癌的研究,6项关于局限性肾癌的研究,2篇评估无论疾病状态(转移性或局限性)的肾癌患者的NLR的文章。

结果

对于局限性RCC,NLR>3预示复发风险降低(风险比=1.63[1.15,2.29])。NLR对转移性或局部晚期RCC的预后价值更强。NLR>3预示总生存期延长(风险比=1.55[1.36,1.76])、无进展生存期延长(风险比=3.19[2.23,4.57])以及对全身治疗有反应。

结论

在当前实践中,NLR是一种简单且廉价的预后因素,可能会改善肾肿瘤学中使用的列线图的预后性能。

相似文献

1
The prognostic value of the neutrophil-lymphocyte ratio in renal oncology: A review.中性粒细胞与淋巴细胞比值在肾脏肿瘤学中的预后价值:综述
Urol Oncol. 2017 Apr;35(4):135-141. doi: 10.1016/j.urolonc.2017.01.016. Epub 2017 Feb 21.
2
Effect of hypertension on preoperative neutrophil-lymphocyte ratio evaluation of prognosis of renal cell carcinoma.高血压对肾细胞癌预后术前中性粒细胞与淋巴细胞比值评估的影响。
Urol Oncol. 2016 May;34(5):239.e9-15. doi: 10.1016/j.urolonc.2015.12.006. Epub 2016 Jan 21.
3
Prognostic impact of neutrophil-to-lymphocyte ratio in renal cell carcinoma: a systematic review and meta-analysis.中性粒细胞与淋巴细胞比值对肾细胞癌预后的影响:系统评价和荟萃分析。
Immunotherapy. 2019 May;11(7):631-643. doi: 10.2217/imt-2018-0175.
4
Elevated neutrophil-lymphocyte ratio combined with hyponatremia indicate poor prognosis in renal cell carcinoma.中性粒细胞与淋巴细胞比值升高合并低钠血症提示肾癌预后不良。
Acta Oncol. 2020 Jan;59(1):13-19. doi: 10.1080/0284186X.2019.1654128. Epub 2019 Aug 26.
5
The impact of neutrophil-lymphocyte ratio on risk reclassification of patients with advanced renal cell cancer to guide risk-directed therapy.中性粒细胞与淋巴细胞比值对晚期肾细胞癌患者风险再分类以指导风险导向治疗的影响。
Acta Oncol. 2020 Jan;59(1):20-27. doi: 10.1080/0284186X.2019.1656342. Epub 2019 Aug 29.
6
Prognostic role of the neutrophil-lymphocyte ratio in renal cell carcinoma: a meta-analysis.中性粒细胞与淋巴细胞比值在肾细胞癌中的预后作用:一项荟萃分析。
BMJ Open. 2015 Apr 8;5(4):e006404. doi: 10.1136/bmjopen-2014-006404.
7
Prognostic value of neutrophil-to-lymphocyte ratio in patients with metastatic renal cell carcinoma treated with first-line and subsequent second-line targeted therapy: A proposal of the modified-IMDC risk model.中性粒细胞与淋巴细胞比值在接受一线及后续二线靶向治疗的转移性肾细胞癌患者中的预后价值:改良IMDC风险模型的提议
Urol Oncol. 2017 Feb;35(2):39.e19-39.e28. doi: 10.1016/j.urolonc.2016.10.001. Epub 2016 Nov 4.
8
Prognostic Significance of Preoperative Neutrophil-to-Lymphocyte Ratio in Nonmetastatic Renal Cell Carcinoma: A Large, Multicenter Cohort Analysis.术前中性粒细胞与淋巴细胞比值在非转移性肾细胞癌中的预后意义:一项大型多中心队列分析
Biomed Res Int. 2016;2016:5634148. doi: 10.1155/2016/5634148. Epub 2016 Nov 6.
9
Pre-treatment neutrophil-to-lymphocyte ratio predicts tumor pathology in newly diagnosed renal tumors.治疗前中性粒细胞与淋巴细胞比值可预测新诊断肾肿瘤的肿瘤病理学特征。
World J Urol. 2016 Dec;34(12):1693-1699. doi: 10.1007/s00345-016-1821-7. Epub 2016 Apr 6.
10
Meta-analysis of the efficacy of the pretreatment neutrophil-to-lymphocyte ratio as a predictor of prognosis in renal carcinoma patients receiving tyrosine kinase inhibitors.对接受酪氨酸激酶抑制剂治疗的肾癌患者,治疗前中性粒细胞与淋巴细胞比值作为预后预测指标疗效的Meta分析。
Oncotarget. 2016 Jul 12;7(28):44039-44046. doi: 10.18632/oncotarget.9836.

引用本文的文献

1
Splenic index score as a predictor of outcomes in metastatic non small cell lung cancer patients treated with immune checkpoint inhibitors.脾指数评分作为接受免疫检查点抑制剂治疗的转移性非小细胞肺癌患者预后的预测指标。
Sci Rep. 2025 May 6;15(1):15781. doi: 10.1038/s41598-025-00708-w.
2
Systemic Inflammatory Markers as Prognostic Factors in Oral Squamous Cell Carcinoma of the Tongue.全身炎症标志物作为舌部口腔鳞状细胞癌的预后因素
Biomedicines. 2025 Mar 20;13(3):754. doi: 10.3390/biomedicines13030754.
3
Prognostic value of the neutrophil‑to‑lymphocyte ratio in renal cell carcinoma: A systematic review and meta‑analysis.
中性粒细胞与淋巴细胞比值在肾细胞癌中的预后价值:一项系统评价和荟萃分析
Oncol Lett. 2025 Mar 13;29(5):231. doi: 10.3892/ol.2025.14977. eCollection 2025 May.
4
Combining clinical characteristics with CT radiomics to predict Ki67 expression level of small renal mass based on artificial intelligence algorithms.结合临床特征与CT影像组学,基于人工智能算法预测小肾肿块的Ki67表达水平。
Front Oncol. 2025 Feb 21;15:1541143. doi: 10.3389/fonc.2025.1541143. eCollection 2025.
5
Association of baseline inflammatory biomarkers and clinical outcomes in patients with advanced renal cell carcinoma treated with immune checkpoint inhibitors.晚期肾细胞癌患者接受免疫检查点抑制剂治疗时基线炎症生物标志物与临床结局的关联
Ther Adv Med Oncol. 2025 Feb 12;17:17588359251316243. doi: 10.1177/17588359251316243. eCollection 2025.
6
Prognostic significance of peripheral blood biomarkers in patients with advanced renal cell carcinoma treated with nivolumab and ipilimumab-a polish multicenter, observational study.纳武单抗和伊匹单抗治疗晚期肾细胞癌患者外周血生物标志物的预后意义——一项波兰多中心观察性研究
Clin Exp Med. 2025 Jan 23;25(1):45. doi: 10.1007/s10238-024-01544-4.
7
Evaluation of prognostic factors for late recurrence in clear cell renal carcinoma: an institutional study.透明细胞肾细胞癌晚期复发的预后因素评估:一项机构研究。
Front Oncol. 2024 Oct 7;14:1446953. doi: 10.3389/fonc.2024.1446953. eCollection 2024.
8
Systemic immune inflammation index (SII) assessment as a potential tool against childhood hypertension.系统性免疫炎症指数(SII)评估作为对抗儿童高血压的潜在工具。
Pediatr Res. 2025 Feb;97(2):467-468. doi: 10.1038/s41390-024-03633-2. Epub 2024 Oct 11.
9
The role of spleen volume change in predicting immunotherapy response in metastatic renal cell carcinoma.脾脏体积变化在预测转移性肾细胞癌免疫治疗反应中的作用。
BMC Cancer. 2023 Oct 30;23(1):1045. doi: 10.1186/s12885-023-11558-y.
10
Second-Line Treatment of Metastatic Renal Cell Carcinoma in the Era of Predictive Biomarkers.预测性生物标志物时代转移性肾细胞癌的二线治疗
Diagnostics (Basel). 2023 Jul 20;13(14):2430. doi: 10.3390/diagnostics13142430.